Samsung Biologics Logs $323M Contract as Biosecure Act Redirection Enters Procurement Data
· techtimes.com · popularity 18/100 · 0 similar stories today · Corporate News & M&A (Business & Finance)
Read the original at techtimes.com →
Summary
Samsung Biologics filed a KRX disclosure naming the US Biosecure Act as sourcing rationale for a $323 million biologics manufacturing contract, marking the first time the federal law appears as a documented client rationale in Korean procurement data. The five-year deal, valued at KRW 434.3 billion, adds to Samsung Biologics' backlog now exceeding $22 billion.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 10.